Drugs / Irsogladine
Irsogladine
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03509831 | Nov 2017 → Jan 2018 | gastritis | Kukje Pharma | Unknown | No outcome recorded |
| Phase 1 | NCT02759224 | Apr → Jul 2016 | gastric ulcer | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02581696 | Aug → Nov 2015 | peptic ulcer disease | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05249725 | Apr → Aug 2022 | gastrointestinal mucositis | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irsogladine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05249725 ↗ |
| Known as | Gaslon | ChEMBL registry synonym — accepted as the source's own label CHEMBL136497 ↗ |
| Known as | Irsogladina | ChEMBL registry synonym — accepted as the source's own label CHEMBL136497 ↗ |
| Known as | IRSOGLADINE MALEATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL136497 ↗ |
| Known as | MN-1695 | ChEMBL registry synonym — accepted as the source's own label CHEMBL136497 ↗ |
| Known as | NSC-759836 | ChEMBL registry synonym — accepted as the source's own label CHEMBL136497 ↗ |
| Modality | Small molecule | — CHEMBL136497 ↗ |
| Route | Oral | “Orally administration of irsogladine maleate 4mg/day, for 8 weeks.” NCT05249725 ↗ |